Until we have a safe, effective COVID-19 vaccine, the world can only hope to manage its spread with the help of tests in hospitals, homes, sports events, airports, schools.
But there’s a problem.
Test demand is already straining supply.
So much so, the U.S. Congress may soon consider legislation to ensure there are enough tests to go around. According to former U.S. FDA Commissioner Scott Gottlieb, and Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy:
“Washington could contract with commercial labs and point-of-care test manufacturers to develop and maintain diagnostic capacity for a crisis. Think of it as part of the national stockpile. Under such contracts, companies would build more labs and sprinkle them throughout the country so capacity could be available wherever it’s needed.”
On top of that, demand issues could get worse with colleges this Fall. Already, schools and are planning to regularly test students and staff on campus to keep people safe.
With that in mind, some of the top COVID-19 test stocks to consider include:
· Co-Diagnostics (CODX)
· Quest Diagnostics (DGX)
· Abbott Laboratories (ABT)